TransCode Therapeutics Announces Public Offering Of Common Stock; No Size Or Amount Disclosed
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) has announced the commencement of an underwritten public offering of its common stock. The company also expects to grant the underwriters a 45-day option to purchase additional shares equal to 15% of the shares offered in the public offering. The offering is subject to market and other conditions, and there is no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. ThinkEquity is acting as sole book-running manager for the offering.
October 26, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TransCode Therapeutics is planning a public offering of its common stock, which could potentially dilute existing shares. The final impact on the stock price will depend on the terms and size of the offering, which have not been disclosed yet.
Public offerings often lead to dilution of existing shares, which can put downward pressure on the stock price. However, the final impact will depend on the terms and size of the offering, which have not been disclosed yet. Therefore, there is some uncertainty regarding the potential impact on the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100